David L Simmons

Summary

Affiliation: Wyeth Research
Country: USA

Publications

  1. ncbi Anti-adhesion therapies
    David L Simmons
    Inflammation Discovery Research, Wyeth Research, 200 CambridgePark Drive, Cambridge, MA02140, USA
    Curr Opin Pharmacol 5:398-404. 2005
  2. ncbi What makes a good anti-inflammatory drug target?
    David L Simmons
    Inflammation Discovery Research, Wyeth Research, 200 Cambridge Park Drive, Cambridge, MA 02140, USA
    Drug Discov Today 11:210-9. 2006
  3. ncbi Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis
    Suzana Marusic
    Department of Inflammation, Wyeth Research, Cambridge, MA 02140, USA
    J Exp Med 202:841-51. 2005

Detail Information

Publications3

  1. ncbi Anti-adhesion therapies
    David L Simmons
    Inflammation Discovery Research, Wyeth Research, 200 CambridgePark Drive, Cambridge, MA02140, USA
    Curr Opin Pharmacol 5:398-404. 2005
    ..However, the latter therapeutic ran into a surprising safety issue earlier this year and was withdrawn from the market, casting a shadow over what had seemed a promising new drug...
  2. ncbi What makes a good anti-inflammatory drug target?
    David L Simmons
    Inflammation Discovery Research, Wyeth Research, 200 Cambridge Park Drive, Cambridge, MA 02140, USA
    Drug Discov Today 11:210-9. 2006
    ....
  3. ncbi Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis
    Suzana Marusic
    Department of Inflammation, Wyeth Research, Cambridge, MA 02140, USA
    J Exp Med 202:841-51. 2005
    ..Our data indicate that cPLA2alpha plays an important role in EAE development and facilitates differentiation of T cells toward the Th1 phenotype...